-$0.34 EPS Expected for Kadmon Holdings, Inc. (KDMN) This Quarter

Wall Street brokerages expect Kadmon Holdings, Inc. (NYSE:KDMN) to report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.26). Kadmon posted earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 32%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 28th.

On average, analysts expect that Kadmon will report full-year earnings of ($1.61) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($1.51). For the next financial year, analysts forecast that the firm will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.89) to ($1.08). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Kadmon.

Kadmon (NYSE:KDMN) last issued its earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. During the same quarter last year, the company earned ($4.24) EPS. The business’s revenue was down 60.0% on a year-over-year basis.

Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Kadmon from a “sell” rating to a “hold” rating in a report on Tuesday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Kadmon in a report on Friday, November 17th. Finally, WBB Securities cut shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price target on the stock. in a report on Monday, October 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $9.75.

Shares of Kadmon (KDMN) traded down $0.09 during trading on Friday, hitting $3.55. 1,110,200 shares of the stock traded hands, compared to its average volume of 289,980. Kadmon has a 1 year low of $2.05 and a 1 year high of $5.93.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Kadmon by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the period. Sphera Funds Management LTD. purchased a new position in Kadmon during the third quarter valued at $3,685,000. Crestline Management LP purchased a new position in Kadmon during the third quarter valued at $2,011,000. Sabby Management LLC purchased a new position in Kadmon during the second quarter valued at $2,112,000. Finally, Susquehanna International Group LLP lifted its position in Kadmon by 3,211.2% during the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after buying an additional 429,752 shares during the period. 51.90% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/12/0-34-eps-expected-for-kadmon-holdings-inc-kdmn-this-quarter.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply